Pain Management

Therapeutic Patch for Pain Relief Shown Effective in Study

Published on

ActiPatch-Muscle-Joint-Mode-Color-Cropped-JPEG-1024x951

BioElectronics Corporation, Frederick, Md,  released updated results of its “Try It and Tell Us” 7-day ActiPatch sample program for United Kingdom and Ireland residents who were surveyed about their experience. The data now includes responses from 856 consumers suffering from chronic pain caused by a number of musculoskeletal conditions.   

A media release from BioElectronics states that its surveys show that most chronic pain relief sufferers have very high baseline pain levels, underscoring a need for new effective and drug-free pain therapies. “By expanding the number of participants evaluating ActiPatch Therapy, we have been able to demonstrate favorable responses in more common causes of chronic pain, including osteoarthritis, rheumatoid arthritis, fibromyalgia, postsurgical chronic pain, and neuropathic pain, as well as analyze the data by location, including chronic back, knee, hip and shoulder pain,” says Ian Rawe, PhD, director of clinical research at BioElectronics Corporation.

The company reports that efficacy rates and pain reduction for those who reported efficacy by specific disease and location were:

  • Chronic pain efficacy rate was 76% with a 4.35 VAS (visual analogue scale) point (51%) pain reduction
  • Osteoarthritis efficacy rate was 80% with a 4.49 VAS point (52%) pain reduction
  • Rheumatoid arthritis efficacy rate was 80% with a 4.50 VAS point (50%) pain reduction
  • Fibromyalgia efficacy rate was 75% with a 4.07 VAS point (47%) pain reduction
  • Chronic postsurgery pain efficacy rate was 76% with a 4.19 VAS point (48%) pain reduction
  • Neuropathy pain efficacy rate was 69% with a 4.55 VAS point (53%) pain reduction
  • Chronic back pain efficacy rate was 76% with a 4.26 VAS point (50%) pain reduction
  • Chronic knee pain efficacy rate was 80% with a 4.84 VAS point (58%) pain reduction
  • Chronic shoulder pain efficacy rate was 80% with a 4.32 VAS point (51%) pain reduction
  • Chronic hip pain efficacy rate was 82% with a 4.40 VAS point (51%) pain reduction

A detail of the survey responses is available here  www.bielcorp.com/clinical-evidence/musculoskeletal-pain.

[Source: BioElectronics Corporation]